Navigation Links
GlaxoSmithKline Responds to JAMA Article on the ICES Thiazolidinediones and Cardiovascular Outcomes in Older Patients with Diabetes
Date:12/11/2007

ater than 70 years of age, and demonstrated the safety profile of rosiglitazone to be consistent with the control medicine (sulfonylurea).

Importantly, the results of this study do not reproduce what is already known about the risk of CHF in TZD users. TZDs can cause fluid retention which can lead to or exacerbate heart failure. TZDs also have a similar increased risk of CHF. Yet, in this analysis, pioglitazone is not associated with an increased risk of CHF (Adjusted RR of 0.91 (95% CI = 0.52-1.59) whereas rosiglitazone is associated with 2 fold-increased risk of CHF (Adjusted RR = 1.98 and 95% CI=1.44-2.72) compared to oral anti-diabetic combination therapy. This is inconsistent with the product labeling.

Moreover, the authors of this retrospective analysis fail to acknowledge the findings of large epidemiological studies, encompassing over 1.3 million patients with type 2 diabetes, as well as other similar studies presented during the recent FDA Advisory Committee meeting. These studies have investigated whether use of rosiglitazone in the real world setting is associated with an increase in myocardial infarction or coronary revascularization. The majority of these studies show that rosiglitazone is not associated with an increased risk of myocardial infarction compared to other anti-diabetic agents.

GSK cites the following as examples of the limitations of this retrospective analysis:

-- As the authors state, patients on TZDs in their analysis may represent

an older, select group of patients with advanced diabetes and therefore

higher baseline risk for cardiovascular disease.

-- The ODB database is composed of a select group of patients.

Rosiglitazone is only prescribed for those patients who fail

treatment on metformin and sulfonylurea, or for whom sulfonylurea or

metformin are contraindicated. The rosiglitazone patients are

therefore ones with higher
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. GlaxoSmithKline Recognizes University of Michigans Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award
2. AUDIO from Medialink and GlaxoSmithKline: Fiber Key in Managing Irritable Bowel Syndrome (IBS) Symptoms
3. Exelixis Submits XL880 Diligence Report to GlaxoSmithKline
4. GlaxoSmithKline Awarded U.S. Department of Defense Contract to Pursue Novel Antibacterial Research Program
5. GlaxoSmithKline and Anacor Pharmaceuticals Form Alliance to Develop Systemic Antivirals and Antibiotics Based on Boron Chemistry
6. BioWa Announces Licensing of BioWas POTELLIGENT(R) Technology by GlaxoSmithkline for Use in Antibody Research and Development
7. GlaxoSmithKline Consumer Healthcare Recommends Maintaining FDAS Current Two-Class Drug System
8. ImmuneRegen Responds to Defense Threat Reduction Agency Request for Information
9. Updated Drug Development Scrip Report Responds to the Pharma Industrys Major Changes
10. Michigan Catholic Conference Responds to Formation of Embryonic Stem Cell Research Ballot Committee
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... 2015  The Paul G. Allen Family Foundation announced ... to six groups of researchers with projects at the ... neuroscience: growing mature human brain cells in the laboratory. ... million over three years.  "This new ... especially significant because the field of neuronal maturation is ...
(Date:4/30/2015)... 2015 Available in select spas ... , Fleur’s introduces CC CRÈME ... benefits of makeup, skin care and solar protection ... is designed with specific complexion-correcting pigments to instantly ... and a healthy glow. Far more than a ...
(Date:4/29/2015)... According to a new market ... (Portable & Non-Portable), Component (Accelerometer, Proximity Probe, & ... & Mining, & Others), & Geography - Global ... to reach $1,453.76 Million by 2020, at a ... tables and 92 figures spread through 205 pages ...
(Date:4/29/2015)... AlloSource ®, one of the ... and soft-tissue allografts for use in surgical procedures ... the launch of AlloSkin™ AC, an acellular dermal ... (CMS) also moved AlloSkin™ RT, a meshed human ... category for reimbursement. "AlloSource is committed ...
Breaking Biology Technology:The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 2The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 3The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 4The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 5Fleur’s Introduces CC CRÈME Perfect Skin Solution 2Fleur’s Introduces CC CRÈME Perfect Skin Solution 3Vibration Monitoring Equipment (Portable & Non-Portable) Market worth $1,453.76 Million by 2020 - New Report by MarketsandMarkets 2Vibration Monitoring Equipment (Portable & Non-Portable) Market worth $1,453.76 Million by 2020 - New Report by MarketsandMarkets 3Vibration Monitoring Equipment (Portable & Non-Portable) Market worth $1,453.76 Million by 2020 - New Report by MarketsandMarkets 4AlloSource Announces New Possibilities In Wound Care 2
... EMERYVILLE, Calif., Jan. 3, 2012  Bionovo, Inc. (NASDAQ: ... discovery and development of safe and effective treatments for ... entered into a $5 million securities purchase agreement with ... Socius Capital Group, LLC. (Logo: ...
... Jan. 3, 2012 Dear NeoStem Shareholders, ... back at 2011 - a transformative year for NeoStem (NYSE Amex: ... term catalysts that we expect to move the company forward in ... Progenitor Cell Therapy, LLC ("PCT") and Amorcyte, LLC ("Amorcyte"). , ...
... NEW YORK, Jan. 3, 2012 Reportlinker.com ... is available in its catalogue: ... http://www.reportlinker.com/p0203539/Cytogenetics---technologiesmarkets-and-companies.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Genomics ... cytogenetics in a broader sense rather than ...
Cached Biology Technology:Bionovo Announces $5 Million Financing 2Bionovo Announces $5 Million Financing 3Bionovo Announces $5 Million Financing 4NeoStem's CEO Letter to Shareholders 2NeoStem's CEO Letter to Shareholders 3NeoStem's CEO Letter to Shareholders 4Cytogenetics - Technologies, Markets and Companies 2Cytogenetics - Technologies, Markets and Companies 3Cytogenetics - Technologies, Markets and Companies 4Cytogenetics - Technologies, Markets and Companies 5Cytogenetics - Technologies, Markets and Companies 6Cytogenetics - Technologies, Markets and Companies 7Cytogenetics - Technologies, Markets and Companies 8Cytogenetics - Technologies, Markets and Companies 9Cytogenetics - Technologies, Markets and Companies 10Cytogenetics - Technologies, Markets and Companies 11
(Date:4/14/2015)... April 14, 2015  HYPR Corp. today announced ... ® ) Alliance tm , an industry consortium ... commit to share technology and collaborate to deliver ... interoperable, more secure and private, and easier to ... verification that protects sensitive user information and eliminates ...
(Date:4/9/2015)... Calif. , April 9, 2015 Synaptics ... interface solutions, announced today that it will report financial ... Thursday, April 23, 2015, after the close of market. ... analysts and investors at 2:00 p.m. PT (5:00 p.m. ... To participate on the live call, analysts ...
(Date:4/2/2015)... , April 2, 2015 ... Q1 2015 attributed to somewhat higher than 125 MSEK. ... the year-end report 2014 that revenues for Q1 2015 ... the company reported for Q4 2014. The operating result ... be negative. The complete interim report will as previously ...
Breaking Biology News(10 mins):HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3Synaptics to Report Third Quarter Results on April 23 2Fingerprint Cards Revises Revenues for Q1 2015 2
... Lolle and colleagues from Purdue University published a paper in ... do not obey the laws of Mendelian inheritance (the idea ... found that these plants were demonstrating genetic traits from older ... of how genes are passed on. At the ...
... Bethesda, MD The Federation of American Societies ... registration for the Science Research Conference (SRC): Mechanism ... 2013 FASEB Science Research Conference on Mechanism and ... 23 in Saxton Rivers, VT. The "Vermont Transcription ...
... mid-nineteenth century, maps have helped elucidate the deadly mysteries ... global mapping of infectious diseases is considerably unreliable and ... outbreaks, according to a new systematic mapping review of ... the 355 infectious diseases assessed in the review, 174 ...
Cached Biology News:Defying the laws of Mendelian inheritance 2Avoiding a cartography catastrophe 2
Request Info...
...
... to Atrophin 1 ( Abpromise for ... Synthetic peptide conjugated to KLH derived ... of Human Atrophin 1.(Note: the amino acid ... .) Entrez GeneID: ...
An excellent carbonyl-reactive FRET quencher paired with Trp or Tyr. Minimum Purity: 95%. Abs(max): ~350 nm; Em(max): none. Solvent System:DMSO or DMF....
Biology Products: